Clinical Trials
33 trialsSafety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors
Myeloid Therapeutics
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Kestrel Therapeutics, Inc.
panSOHO
Bayer
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
ModeX Therapeutics, An OPKO Health Company
LEAP-005
Merck Sharp & Dohme LLC
ANTARES
Instituto do Cancer do Estado de São Paulo
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Sotio Biotech Inc.
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
SystImmune Inc.
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
AstraZeneca
PETRA
AstraZeneca
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
SEED Therapeutics, Inc.
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)
Daiichi Sankyo
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
DualityBio Inc.
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
Seagen Inc.
LNCB74-01
NextCure, Inc.
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Tanabe Pharma America, Inc.
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Eli Lilly and Company
KEYNOTE 158
Merck Sharp & Dohme LLC
A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
Bolt Biotherapeutics, Inc.
A Study of Patients Receiving High-Dose Rate Brachytherapy
National Institutes of Health Clinical Center (CC)
A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors
Incyte Corporation
Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors
Yuhan Corporation
START-001
Marengo Therapeutics, Inc.
MasterKey-01
Black Diamond Therapeutics, Inc.
Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors
Zhejiang Yangli Pharmaceutical Technology Co., Ltd.
XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.
Evopoint Biosciences Inc.
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Carisma Therapeutics Inc
Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer
Vincerx Pharma, Inc.
Milademetan in Advanced/Metastatic Solid Tumors
Rain Oncology Inc
VUBAR
Universitair Ziekenhuis Brussel
A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors
ZielBio, Inc.
A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors
Silverback Therapeutics
Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.
Mannkind Corporation